Dermatology

>

Latest News

FDA Accepts sNDA for Roflumilast Cream 0.05% to Treat Atopic Dermatitis in Children Aged 2 to 5 Years  / image credit DOCS Dermatology Rocco Serrao, MD
FDA Accepts sNDA for Roflumilast Cream 0.05% to Treat Atopic Dermatitis in Children Aged 2 to 5 Years

December 16th 2024

Arcutis Biotherapeutics announced submission of the sNDA today, citing the the supporting positive data from the phase 3 INTEGUMENT-PED and INTEGUMENT-OLE trials.

FDA Approves Nemolizumab for Treatment of Moderate-to-Severe Atopic Dermatitis / Image credit: ©Argus/AdobeStock
FDA Approves Nemolizumab for Treatment of Moderate-to-Severe Atopic Dermatitis

December 16th 2024

Tapinarof Cream, 1%, Gets FDA Green Light for Atopic Dermatitis in Individuals Aged 2 Years and Older / image credit ©Waldenmarus/stock.adobe.com
Tapinarof Cream, 1%, Gets FDA Green Light for Atopic Dermatitis in Individuals Aged 2 Years and Older

December 16th 2024

Upadacitinib Effective for Atopic Dermatitis in Adolescents at 76 Weeks: RCT Analysis / image credit: Amy S Paller, MS, MD  Courtesy of Northwestern Medicine
Upadacitinib Safe and Effective for Atopic Dermatitis in Adolescents at 76 Weeks: RCT Analysis

December 11th 2024

Dupilumab Effective for Severe Atopic Dermatitis at 5 Years: Daily Dose / image credit: ©New Africa/AdobeStock
Dupilumab Effective for Severe Atopic Dermatitis at 5 Years: Daily Dose

November 7th 2024

Latest CME Events & Activities

21st Annual International Symposium on Melanoma and Other Cutaneous Malignancies®

February 8, 2025

View More

Expert Illustrations & Commentaries™: Picturing the Potential Role of OX40 and OX40L Inhibitors in Atopic Dermatitis

View More

Hidradenitis Suppurativa (HS): Deepening Foundations of Knowledge in Disease Pathogenesis, Disease Severity Assessment, and Treatment Decision-Making

View More

Tumor-Infiltrating Lymphocyte Therapy Advances Into Melanoma

View More

Community Practice Connections™: 20th Annual International Symposium on Melanoma and Other Cutaneous Malignancies

View More

Clinical Consultations™: Optimizing Treatment Outcomes for Patients with Generalized Pustular Psoriasis

View More

Advances in™ Atopic Dermatitis: Addressing Unmet Needs in Patients With Skin of Color

View More

Clinical Consultations™: Guiding Patients with Genital Psoriasis Toward Relief Through a Multidisciplinary Approach

View More

Patient, Provider & Caregiver Connection™: Understanding the Patient Journey to Provide Personalized Care for Generalized Pustular Psoriasis

View More

Cases and Conversations™: Applying Practice Techniques to Optimize Diagnosis and Treatment Strategies in Generalized Pustular Psoriasis

View More

Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice

View More

‘REEL’ Time Patient Counseling™: Fostering Effective Conversations in Practice to Create a Visible Impact for Patients Living with Genital Psoriasis

View More

Dermalorian™ Webinar: Shedding Light on Patient-Reported Outcomes to Assess Disease Severity in Patients With Atopic Dermatitis

View More

Where Do Biologics Fit Into the Management of Moderate-to-Severe Atopic Dermatitis?

View More

More News

© 2024 MJH Life Sciences

All rights reserved.